Ambrx Biopharma Inc
NYSE:AMAM
Intrinsic Value
Ambrx Biopharma Inc. operates as a clinical-stage biologics company. [ Read More ]
The intrinsic value of one AMAM stock under the Base Case scenario is 0.63 USD. Compared to the current market price of 28 USD, Ambrx Biopharma Inc is Overvalued by 98%.
Valuation Backtest
Ambrx Biopharma Inc
Run backtest to discover the historical profit from buying and selling AMAM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ambrx Biopharma Inc
Current Assets | 233.8m |
Cash & Short-Term Investments | 225.3m |
Receivables | 2.4m |
Other Current Assets | 6.1m |
Non-Current Assets | 37.7m |
PP&E | 12.6m |
Intangibles | 24.8m |
Other Non-Current Assets | 300k |
Current Liabilities | 18.3m |
Accounts Payable | 5.1m |
Accrued Liabilities | 12.7m |
Other Current Liabilities | 500k |
Non-Current Liabilities | 10.8m |
Other Non-Current Liabilities | 10.8m |
Earnings Waterfall
Ambrx Biopharma Inc
Revenue
|
5.7m
USD
|
Operating Expenses
|
-94m
USD
|
Operating Income
|
-88.3m
USD
|
Other Expenses
|
5.7m
USD
|
Net Income
|
-82.6m
USD
|
Free Cash Flow Analysis
Ambrx Biopharma Inc
AMAM Profitability Score
Profitability Due Diligence
Ambrx Biopharma Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Ambrx Biopharma Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
AMAM Solvency Score
Solvency Due Diligence
Ambrx Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Ambrx Biopharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMAM Price Targets Summary
Ambrx Biopharma Inc
According to Wall Street analysts, the average 1-year price target for AMAM is 28.67 USD .
Ownership
AMAM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AMAM Price
Ambrx Biopharma Inc
Average Annual Return | -62.11% |
Standard Deviation of Annual Returns | 21.06% |
Max Drawdown | -98% |
Market Capitalization | 1.8B USD |
Shares Outstanding | 63 289 200 |
Percentage of Shares Shorted | 3.28% |
AMAM News
Last Important Events
Ambrx Biopharma Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Ambrx Biopharma Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ambrx Biopharma Inc. operates as a clinical-stage biologics company. The company is headquartered in La Jolla, California and currently employs 70 full-time employees. The company went IPO on 2021-06-18. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation. Its SAA incorporation technology allows to develop a wide array of product candidate modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates (ISACs). Its lead ADC candidate is ARX788, an anti-HER2 ADC, being investigated in multiple clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer and other solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one AMAM stock under the Base Case scenario is 0.63 USD.
Compared to the current market price of 28 USD, Ambrx Biopharma Inc is Overvalued by 98%.